TY - JOUR
T1 - Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells
AU - Zhou, W.
AU - Tu, Y.
AU - Simpson, P. J.
AU - Kuhajda, F. P.
N1 - Funding Information:
This study was supported by a grant from the Department of Defense Breast Cancer Grant BC050452 to FPK. We thank FASgen Inc. for the generous gift of MPA.
PY - 2009/8/20
Y1 - 2009/8/20
N2 - Fatty acid synthase (FAS) inhibition initiates selective apoptosis of cancer cells both in vivo and in vitro, which may involve malonyl-CoA metabolism. These findings have led to the exploration of malonyl-CoA decarboxylase (MCD) as a potential novel target for cancer treatment. MCD regulates the levels of cellular malonyl-CoA through the decarboxylation of malonyl-CoA to acetyl-CoA. Malonyl-CoA is both a substrate for FAS and an inhibitor of fatty acid oxidation acting as a metabolic switch between anabolic fatty acid synthesis and catabolic fatty acid oxidation. We now report that the treatment of human breast cancer (MCF7) cells with MCD small interference RNA (siRNA) reduces MCD expression and activity, reduces adenosine triphosphate levels, and is cytotoxic to MCF7 cells, but not to human fibroblasts. In addition, we synthesized a small-molecule inhibitor of MCD, 5-(Morpholine-4- carbonyl)-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl] -amino-pentanoic acid methyl ester (MPA). Similar to MCD siRNA, MPA inhibits MCD activity in MCF7 cells, increases cellular malonyl-CoA levels and is cytotoxic to a number of human breast cancer cell lines in vitro. Taken together, these data indicate that MCD-induced cytotoxicity is likely mediated through malonyl-CoA metabolism. These findings support the hypothesis that MCD is a potential therapeutic target for cancer therapy.
AB - Fatty acid synthase (FAS) inhibition initiates selective apoptosis of cancer cells both in vivo and in vitro, which may involve malonyl-CoA metabolism. These findings have led to the exploration of malonyl-CoA decarboxylase (MCD) as a potential novel target for cancer treatment. MCD regulates the levels of cellular malonyl-CoA through the decarboxylation of malonyl-CoA to acetyl-CoA. Malonyl-CoA is both a substrate for FAS and an inhibitor of fatty acid oxidation acting as a metabolic switch between anabolic fatty acid synthesis and catabolic fatty acid oxidation. We now report that the treatment of human breast cancer (MCF7) cells with MCD small interference RNA (siRNA) reduces MCD expression and activity, reduces adenosine triphosphate levels, and is cytotoxic to MCF7 cells, but not to human fibroblasts. In addition, we synthesized a small-molecule inhibitor of MCD, 5-(Morpholine-4- carbonyl)-[4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl] -amino-pentanoic acid methyl ester (MPA). Similar to MCD siRNA, MPA inhibits MCD activity in MCF7 cells, increases cellular malonyl-CoA levels and is cytotoxic to a number of human breast cancer cell lines in vitro. Taken together, these data indicate that MCD-induced cytotoxicity is likely mediated through malonyl-CoA metabolism. These findings support the hypothesis that MCD is a potential therapeutic target for cancer therapy.
KW - Apoptosis
KW - Fatty acid metabolism
KW - Fatty acid synthase
KW - Malonyl-CoA
KW - Malonyl-CoA decarboxylase
UR - http://www.scopus.com/inward/record.url?scp=69249202281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69249202281&partnerID=8YFLogxK
U2 - 10.1038/onc.2009.160
DO - 10.1038/onc.2009.160
M3 - Article
C2 - 19543323
AN - SCOPUS:69249202281
SN - 0950-9232
VL - 28
SP - 2979
EP - 2987
JO - Oncogene
JF - Oncogene
IS - 33
ER -